Effect of co-administration of fluoxetine and amantadine on immunoendocrine parameters in rats subjected to a forced swimming test

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1050-1060

  Rogóz, Zofia ^a   Kubera, Marta ^a   Rogóz, Katarzyna ^a   Basta Kaim, Agnieszka ^a   Budziszewska, Bogusława ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Amantadine; Corticosterone; Fluoxetine; Interferon ; Interleukin 10; Rats; Splenocyte proliferation

Indexed keywords

AMANTADINE; CONCANAVALIN A; CORTICOSTERONE; FLUOXETINE; INTERLEUKIN 10;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; ENDOCRINE FUNCTION; FORCED SWIMMING TEST; MALE; NONHUMAN; RAT; SPLEEN CELL; SPLEEN WEIGHT;

EID: 76049125481     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70167-7     Document Type: Article

References (70)

1. Aoki FY, Sitar DS: Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet, 1988, 14, 35-51.
2. Azpiroz A, Fano E, Garmendia L, Arregi A, Cacho R, Beitia G, Brain PF: Effects of chronic mild stress (CMS) and imipramine administration, on spleen mononuclear cell proliferative response, serum corticosterone level and brain norepinephrine content in male mice. Psychoneuroendocrinology, 1999, 24, 345-361.
3. Bachen EA, Manuck SB, Marsland AL, Cohen S, Malk-off SB, Muldoon MF, Rabin BS: Lymphocyte subset and cellular immune response to a brief experimental stressor. Psychosom Med, 1992, 54, 673-679.
4. Basso AM, Gioino G, Molin VA, Cancela LM: Chronic amphetamine facilitates immunosuppression in response to a novel aversive stimulus: reversal by haloperidol pretreatment. Pharmacol Biochem Behav, 1999, 62, 307-314.
5. Bauer ME, Perks P, Lightman SL, Shanks N: Restraint stress is associated with changes in glucocorticoid immunoregulation. Physiol Behav, 2001, 73, 525-532.
6. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000, 47, 351-354.
7. Brady LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M: Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. J Clin Invest, 1991, 87, 831-837.
8. Burmester J, Hanpft R, Kroplin K, Lullmann-Rauch R, Patten M: Amantadine-induced lipidosis. Acytological and physicochemical study. Toxicology, 1987, 44, 45-59.
9. Clark C, Woodson MM, Nagasawa HT: Inhibition of lymphocyte proliferation by amantadine and its isomer, 2-aminoadamantane; impact on Lyt-2+ T cells while sparing L3T4+ T cells. Immunopharmacology, 1991, 21, 41-50.
10. Clark C,Woodson MM,Winge VB, Nagasawa HT: The antiviral drug amantadine has a direct inhibitory effect on T-lymphocytes. Immunopharmacology, 1989, 18, 195-204.
11. Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP, Leonard BE: Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav, 2000, 65, 591-597.
12. Connor TJ, Kelly JP, Leonard BE: Forced swim testinduced endocrine and immune changes in the rat: effect of subacute desipramine treatment. Pharmacol Biochem Behav, 1998, 59, 171-177.
13. Connor TJ, Leonard BE: Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci, 1998, 62, 583-606.
14. Cox JH, Ford WL: The migration of lymphocytes across specialized vascular endotelium. IV. Prednisolone acts at several points on the recirculation pathway of lymphocytes. Cell Immunol, 1982, 66, 407-422.
15. Dhabhar FS, Miller AH, McEwen BS, Spencer RL: Effects of stress on immune cell distribution. Dynamics and hormonal mechanisms. J Immunol, 1995, 54, 5511-5527.
16. Dietrich DE, Bode L, Spannhuth CW, Lau T, Huber TJ, Brodhun B, Ludwig H et al.: Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipol Dis, 2000, 2, 65-70.
17. Duncan GE, Knapp DJ, Carson SW, Breese GR: Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone. J Pharmacol Exp Ther, 1998, 285, 579-589.
18. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev, 2000, 52, 595-638.
19. Fadda P, Pani L, Porcella A, Fratta W: Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. Neurosci Lett, 1995, 192, 121-123.
20. Ferszt R, Kühl K-P, Bode L, Severus EW, Winzer B, Berghöfer A, Beelitz G et al.: Amantadine revisited: an open trial of amantadine sulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry, 1999, 32, 142-147.
21. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol, 1991, 146, 3444-3451.
22. Frick LR, Palumbo MJ, Zappla MP, Brocco MA, Cremaschi GA, Genaro AM: Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T cell response by serotonin dependent and independent mechanisms. Biochem Pharmacol, 2008, 75, 1817-1826.
23. Frick LR, Rapanelli M, Cremaschi GA, Genaro AM: Fluoxetine directly counteracted the adverse effects of chronic stress on T cell immunity by compensatory and specific mechanisms. Brain Behav Immun, 2009, 23, 36-40.
24. Hasko G, Szabo C, Nemeth ZH, Salzman AL, Vizi ES: Stimulation of β-adrenoceptors inhibits endotoxin-induced IL-12 production in normal and IL-10 deficient mice. J Neuroimmunol, 1998, 88, 57-61.
25. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F.: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry, 1996, 153, 93-99.
26. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocrine Rev, 1985, 17, 187-205.
27. Holsboer F, Gerken A, Stalla GK, Muller OA: ACTH, cortisol and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery. Biol Psychiatry, 1985, 20, 276-286.
28. Hostetler KY, Richman DD: Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells. Biochem Pharmacol, 1982, 31, 3795-3799.
29. Huber TJ, Dietrich DE, Emrich HM: Possible use of amantadine in depression. Pharmacopsychiatry, 1999, 32, 47-55.
30. Josefsson E, Bergquist J, Ekman R, Tarkowski A: Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology, 1996, 88, 140-146.
31. Kouassi E, Boukhris W, Descotes J, Zukervar P, Li YS, Revillard, JP: Selective T cell defects induced by dopamine. Administration in mice. Immunopharmacol Immunotoxicol, 1987, 9, 477-487.
32. Kubera M, Basta-Kaim A, Budziszewska B, Rogó̇ Z, Skuza G, Léskiewicz M, Tetich M et al.: Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. Int J Neuropsychopharmacol, 2006, 9, 297-305.
33. Kubera M, Basta-Kaim A, Skowron-Cendrzak A, Mazur-Kolecka B, Roman A, Borycz J.: Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity. Pol J Pharmacol, 1995, 47, 321-326.
34. Kubera M, Basta-Kaim A, Wróbel A, Maes M, Dudek D: Increased mitogen-induced lymphocyte proliferation in treatment resistant depression: a preliminary study. Neuroendocrinol Lett, 2004, 25, 207-210.
35. Kubera M, Filip M, Basta-Kaim A, Nowak E, Budziszewska B, Tetich M, Holan V et al.: The effect of amphetamine sensitization on mouse immunoreactivity. J Physiol Pharmacol, 2002, 53, 233-242.
36. Kubera M, Kenis G, Bosmans E, Scharpe S, Maes M: Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-γ and interleukin-10. Neuropsychopharmacology, 2000, 23, 89-98.
37. Kubera M, Kenis G, Bosmans E, Ziȩba A, Dudek D, Nowak G, Maes M: Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol, 2000, 52, 237-241.
38. Kubera M, Lin A-H, Kenis G, Bosmans E, van Bockstaele D, Maes M: Anti-inflammatory effects of antidepressants through suppression of the interferon-γ/interleukin-10 production ratio. J Clin Psychopharmacol, 2001, 21, 199-206.
39. Kubera M, Maes M: Serotonin-immune interactions in major depression. In: Neuro-immune interactions in neurologic and psychiatric disorders. Eds. Petterson P, Kordon C, Christen Y, Springer-Verlag, Berlin, Heidelberg, 2000, 79-87.
40. Kubera M, Maes M, Budziszewska B, Basta-Kaim A, Lékiewicz M, Grygier B, Rogó̇ Z et al.: Inhibitory effects of amantadine on the production of pro-inflammatory cytokines in human blood. Pharmacol Rep, 2009, 61, 1105-1112.
41. Kubera M, Maes M, Holan V, Basta-Kaim A, Roman A, Shani J: Prolonged desipramine treatment increases the production of interlekin-10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression. J Affect Dis, 2001, 63, 171-178.
42. Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, Claesson M: Effect of chronic treatment with imipramine on interleukin-1 and interleukin-2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol, 1996, 48, 503-506.
43. Lysle D, Cunnick J, Rabin B: Stressor-induced alteration of lymphocyte proliferation in mice: evidence for enhancement of mitogenic responsiveness. Brain Behav Immun, 1990, 4, 269-277.
44. Madden KS, Felten SY, Felten DL, Sundaresan PR, Livnat S: Sympathetic neural modulation of the immune system. I. Depression of T cell immunity in vivo and vitro following chemical sympathectomy. Brain Behav Immun, 1989, 3, 72-89.
45. Madden KS, Moynihan JA, Brenner GJ, Felten SY, Felten DL, Livnat S:. Sympathetic nervous system modulation of the immune system. III. Alterations in T and B cell proliferation and differentiation in vitro following chemical sympathectomy. J Neuroimmunol, 1994, 49, 77-87.
46. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perni G, Kubera M et al.: The inflammatory & neurogenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis, 2009, 24, 27-53.
47. Masuda Y, Kondoh M, Suzuki M, Ohnuma S, Shimizu T, Hishikawa T: Participation of dopamine and norepinephrine in the secretion of interleukin-2 and interleukin-6 from the spleen of mice in different immune responses. Med Sci Res, 1995, 23, 851-852.
48. Meyers CA, Valentine AD, Wong FC, Leeds NE: Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: correlation of SPECT with neuropsychological testing. J Neuropsychiatry Clin Neurosci, 1994, 6, 285-288.
49. Murphy BEP: Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology, 1997, 22, S125-S133.
50. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol, 1978, 47, 379-391.
51. Porter RH, Greenamyre JT: Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem, 1995, 64, 614-623.
52. Ramer-Quinn DS, Baker RA, Sanders VM: Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production. J Immunol, 1997, 159, 4857-4867.
53. Rinner I, Schauenstein K, Mangge H, Porta S, Kvetnansky R: Opposite effects of mild and severe stress on in vitro activation of rat peripheral blood lymphocytes. Brain Behav Immun, 1992, 6, 130-140.
54. Rogó̇ Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lasoń W: Effects of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary- adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol, 2005, 56, 49-61.
55. Rogó̇ Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A: Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep, 2007, 59, 778-784.
56. Rogó̇ Z, Skuza G, Kúmider M, Wójcikowski J, Kot M, Daniel WA: Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol, 2004, 56, 179-185.
57. Rogó̇ Z, Skuza G, Lékiewicz M, Budziszewska B: Effects of co-administration with of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to forced swim test. Pharmacol Rep, 2008, 60, 880-888.
58. Rogó̇ Z, Skuza G, Maj J, Danysz W: Synergistic effect of uncompetitive NMDA receptor antagonists and anti-depressant drugs in the forced swimming test in rats. Neuropharmacology, 2002, 42, 1024-1030.
59. Sanders VM, Straub RH: Norepinephrine, the β-adrenergic receptor, and immunity. Brain Behav Immun, 2002, 16, 290-332.
60. Satoh T, Yamada K, Tsuboi M: Effect of imipramine on serum corticosterone levels in forced swimming rats. Res Comm Psychol Behav, 1985, 10, 235-238.
61. Schiepers OJG, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29, 201-217.
62. Służewska A: Indicators of immune activation in depressed patients. In: Cytokines: Stress and depression. Eds. Dantzer A, Yirmia R, Kluwer Academic/Plenum Publishers, New York, 1999, 59-73.
63. Służewska A, Rybakowski J, Sobieska M, Bosmans E, Pollet H, Wiktorowicz K: Increased levels of alpha-1-acid glycoprotein and interleukin-6 in refractory depression. Depression, 1996, 39, 149-155.
64. Smith RS: The macrophage theory of depression. Med Hypotheses, 1991, 35, 298-306.
65. Stefansky V, Engler H: Effects of acute and chronic social stress on blood cellular immunity in rats. Physiol Behav, 1998, 64, 733-741.
66. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol, 2003, 18, 93-96.
67. + T cells exposed to norepinephrine. J Immunol, 2001, 166, 232-240.
68. Szelenyi J, Selmeczy Z: Immunomodulatory effect of anti-depressants. Curr Opin Pharmacol, 2002, 2, 428-432.
69. Szelenyi J, Vizi ES: The catecholamine cytokine balance. Interaction between the brain and the immune system. Ann NY Acad Sci, 2007, 1113, 311-324.
70. Yamada K, Horita Y, Tsuboi M: Effects of repeated administration of antidepressants on swimming time and corticosterone levels in forced swimming rats. Res Comm Psychol Behav, 1989, 14, 253-256.